Rehovot, Israel
October 18, 2023

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, today provides an update to its investors and stakeholders amidst the ongoing security situation in Israel.

“In these trying times, we extend our heartfelt condolences to those directly and indirectly affected by the recent events in Israel,” said Ofer Haviv, CEO of Evogene. “Despite the challenges, Evogene and its subsidiaries remain steadfast in their commitment to innovation and progress. Our focus and strategy remain stable, and our dedicated team works diligently to fulfill our missions for 2023 and pave the way for 2024. We are grateful for the unwavering support from our partners and stakeholders. We remain attentive and monitor our position and plans as the situation evolves.”

Website: http://www.evogene.com

Published: October 18, 2023